{
    "clinical_study": {
        "@rank": "33502", 
        "arm_group": {
            "arm_group_label": "Arm 1: Device"
        }, 
        "brief_summary": {
            "textblock": "This study aims to investigate prospectively throughout a period of 3- 6  months and not to\n      exceed 12 months (according to local therapeutic plans) patients experiences of treatment\n      with Factor VIII  in the new device named FuseNGO, a new delivery system for Factor VIII\n      compared to their previous  delivery system."
        }, 
        "brief_title": "Evaluation Of Acceptability And Satisfaction Of Hemophilia Patients Treated With FusENGO", 
        "completion_date": {
            "#text": "August 2015", 
            "@type": "Anticipated"
        }, 
        "condition": "Hemophilia A", 
        "condition_browse": {
            "mesh_term": "Hemophilia A"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Male adults (aged 18 to 65 years) with Haemophilia A (all severity levels) who\n             currently use FVIII treatment either prophylactically or on-demand using traditional\n             factor VIII delivery mechanisms.\n\n          -  Patients advised for any reason by their physician to switch to a new factor VIII\n             delivery device,  namely FuseNGO, before receiving any details about this study or\n             Patients who requested to be treated with a new factor VIII delivery device namely\n             FuseNGO, before receiving any details about this study.\n\n        Exclusion Criteria:\n\n          -  Patients not previously recommended by their physician to switch to this new factor\n             VIII delivery system or Patients who did not previously ask their physician to be\n             switched to this new factor VIII delivery system.\n\n          -  Patients for which it is anticipated that 10 infusions will not occur in the 12\n             months following their inclusion in the study."
            }, 
            "gender": "Male", 
            "healthy_volunteers": "No", 
            "maximum_age": "65 Years", 
            "minimum_age": "18 Years", 
            "sampling_method": "Non-Probability Sample", 
            "study_pop": {
                "textblock": "Approximately 200 patients with Hemophilia A (all severity levels) will be enrolled in\n        approximately 20 centers in Italy."
            }
        }, 
        "enrollment": {
            "#text": "200", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "October 8, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01959919", 
            "org_study_id": "B1831081"
        }, 
        "intervention": {
            "arm_group_label": "Arm 1: Device", 
            "description": "Dosage will be chosen by PI based on patient condition.", 
            "intervention_name": "Refacto FusENGO", 
            "intervention_type": "Device"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "lastchanged_date": "May 14, 2014", 
        "link": {
            "description": "To obtain contact information for a study center near you, click here.", 
            "url": "https://trialinfoemail.pfizer.com/pages/landing.aspx?StudyID=B1831081&StudyName=Evaluation%20Of%20Acceptability%20And%20Satisfaction%20Of%20Hemophilia%20Patients%20Treated%20With%20FusENGO"
        }, 
        "location": {
            "facility": {
                "address": {
                    "city": "Napoli", 
                    "country": "Italy", 
                    "zip": "80131"
                }, 
                "name": "Dipartimento Medicina Clinica e Sperimentale"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "Italy"
        }, 
        "number_of_groups": "1", 
        "official_title": "Non Interventional Longitudinal Study To Assess The Acceptability And The Satisfaction Of Patients With Hemophilia A Treated Both On Demand And On Prophylaxis With A New Factor VIII Delivery System FusENGO", 
        "overall_contact": {
            "last_name": "Pfizer CT.gov Call Center", 
            "phone": "1-800-718-1021"
        }, 
        "overall_official": {
            "affiliation": "Pfizer", 
            "last_name": "Pfizer CT.gov Call Center", 
            "role": "Study Director"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 4", 
        "primary_completion_date": {
            "#text": "August 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "measure": "Ease of use, Time taken to reconstitute, Ease of storage, Rapidity to infuse, Impact on daily life of the therapy both on physical and social/ affective  aspects, Perception about the therapy, Satisfaction", 
                "safety_issue": "No", 
                "time_frame": "6 months"
            }, 
            {
                "measure": "Ease of use, Time taken to reconstitute, Ease of storage, Rapidity to infuse, Impact on daily life of the therapy both on physical and social/ affective  aspects, Perception about the therapy, Satisfaction", 
                "safety_issue": "No", 
                "time_frame": "12 months"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01959919"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)", 
                "safety_issue": "No", 
                "time_frame": "6 months"
            }, 
            {
                "measure": "Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)", 
                "safety_issue": "No", 
                "time_frame": "12 months"
            }
        ], 
        "source": "Pfizer", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Pfizer", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "February 2014", 
        "study_design": "Observational Model: Case-Only, Time Perspective: Prospective", 
        "study_type": "Observational", 
        "verification_date": "May 2014"
    }
}